Consensus Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
202.5 ^USD	+0.23%		+6.27%	-21.76%

Apr. 25	Goldman Sachs Adjusts Biogen Price Target to $340 From $393	MT
Apr. 25	Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305	MT

Evolution of the average Target Price on Biogen Inc.

Price target over the last 5 years

History of analyst recommendation changes

8d06b731d400a95b9a4e.U1GT8i2Kj6Sz6HJMO5C4cEcRRUe7Mm-ToZePKDYoM7c.Ch37vELsy-7AuQghcsmLGB0hFz_NXR-m467if0ZPXPYLHau7YcS4nYedNw~29a1217ee4f88cb9057f8f7f767d6fd1

Analyst Recommendations on Biogen Inc.

Goldman Sachs Adjusts Biogen Price Target to $340 From $393	Apr. 25	MT
Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305	Apr. 25	MT
Barclays Adjusts Price Target on Biogen to $200 From $215	Apr. 25	MT
HC Wainwright Adjusts Biogen's Price Target to $300 From $325	Apr. 25	MT
Wedbush Adjusts Price Target on Biogen to $215 From $213	Apr. 25	MT
Morgan Stanley Cuts Biogen's Price Target to $331 From $339	Apr. 24	MT
Piper Sandler Raises Biogen's Price Target to $335 From $325	Apr. 24	MT
RBC Lowers Biogen's Price Target to $317 From $326	Apr. 24	MT
Needham Adjusts Price Target on Biogen to $294 From $300	Apr. 19	MT
BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept	Apr. 19	MT
Oppenheimer Adjusts Biogen Price Target to $270 From $290	Apr. 19	MT
UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating	Apr. 17	MT
Wedbush Cuts Biogen's Price Target to $213 From $245	Apr. 17	MT
Argus Adjusts Biogen's Price Target to $240 From $315	Apr. 15	MT
Goldman Sachs Cuts Biogen's Price Target to $393 From $400	Apr. 15	MT
JPMorgan Cuts Biogen's Price Target to $240 From $270, Maintains Neutral Rating	Apr. 11	MT
Morgan Stanley Trims Price Target on Biogen to $339 From $346, Keeps Overweight Rating	Apr. 09	MT
Barclays Cuts Price Target on Biogen to $215 From $230, Maintains Equalweight Rating	Apr. 04	MT
BIOGEN : Jefferies confirms its Buy rating on the stock	Mar. 19	CF
Canaccord Genuity Adjusts Price Target on Biogen to $305 From $310, Keeps Buy Rating	Feb. 20	MT
UBS Cuts Biogen Price Target to $250 From $276, Maintains Neutral Rating	Feb. 16	MT
Oppenheimer Adjusts Biogen Price Target to $290 From $295, Maintains Outperform Rating	Feb. 14	MT
The market faces a choice	Feb. 14
Baird Adjusts Biogen Price Target to $316 From $333, Maintains Outperform Rating	Feb. 14	MT
Needham Adjusts Biogen Price Target to $300 From $305, Maintains Buy Rating	Feb. 14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

202.5 USD

Average target price

286.5 USD

Spread / Average Target

+41.53%

High Price Target

350 USD

Spread / Highest target

+72.87%

Low Price Target

200 USD

Spread / Lowest Target

-1.22%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Biogen Inc.

Morgan Stanley
Piper Sandler
RBC Capital Markets
Needham & Co.
BMO Capital
Oppenheimer
UBS
Wedbush
Argus
Goldman Sachs
JPMorgan Chase
Barclays
Canaccord Genuity
Wells Fargo Securities
TD Cowen
Stifel Nicolaus
Scotiabank
Baird
BofA Securities
Raymond James
HSBC
Mizuho Securities
Atlantic Equities
Guggenheim
Jefferies & Co.
Truist Securities
Cowen
SVB Securities LLC
HC Wainwright
SVB Leerink
Cantor Fitzgerald
Bernstein
William Blair & Co.
Citigroup
Credit Suisse
DZ Bank

Ratings for Biogen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar